Nov 26, 2024
Dr. Michael Sherling, Co-Founder, Chief Medical Officer, and Strategy Officer at ModMed, aims to save time for physicians and patients by reducing administrative burden through technology. Their AI-based solutions focus on automating mundane tasks like fax routing and documentation and can passively...
Nov 26, 2024
Dr. Michael Sherling, Co-Founder, Chief Medical Officer, and Strategy Officer at ModMed, aims to save time for physicians and patients by reducing administrative burden through technology. Their AI-based solutions focus on automating mundane tasks like fax routing and documentation and can passively...
Nov 25, 2024
Dr. Eric Siemers, Medical Officer at Acumen Pharma, is developing a monoclonal antibody called sabirnetug that targets a specific toxic form of amyloid beta, Aβ oligomers. These oligomers are now believed to be a key driver of neuronal damage in Alzheimer's disease. The drug is in phase 2 clinical trials to evaluate...
Nov 25, 2024
Dr. Eric Siemers, Medical Officer at Acumen Pharma, is developing a monoclonal antibody called sabirnetug that targets a specific toxic form of amyloid beta, Aβ oligomers. These oligomers are now believed to be a key driver of neuronal damage in Alzheimer's disease. The drug is in phase 2 clinical trials to evaluate...
Nov 25, 2024
Rob Abbott, CEO and Executive Director at ISPOR, the Professional Society for Health Economics and Outcomes Research, focuses on defining and measuring value in healthcare, including accessibility, affordability, effectiveness, and patient outcomes. HEOR (health economics and outcomes research) can provide...